Press Releases

2014

March 26, 2014
CytomX Therapeutics to Present Data from Anti-Jagged Probody Program at Upcoming AACR Annual Meeting 2014

January 9, 2014
CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets

2013

October 22, 2013
CytomX Therapeutics Presents Data for First-in-Class Jagged Probody™ Program at AACR-NCI-EORTC International Conference

October 16, 2013
Publication in Science Translational Medicine Highlights Enhanced Therapeutic Index of CytomX Probody™ Therapeutic Compared to Traditional Antibody

October 1, 2013
CytomX Therapeutics to Present at 12th Annual BIO Investor Forum

September 24, 2013
CytomX Therapeutics Named a 2013 “Fierce 15” Biotech Company by FierceBiotech

July 16, 2013
CytomX Announces Appointment of Krishna Polu, M.D., as Chief Medical Officer; Promotion of Debanjan Ray, MBA, to Vice President, Business Development

June 6, 2013
CytomX Announces Global Strategic Collaboration with Pfizer to Develop and Commercialize Multiple Probody™-Drug Conjugates in Oncology

June 3, 2013
CytomX Therapeutics Named a 2013 Red Herring Top 100 North America Tech Startup

May 7, 2013
CytomX Therapeutics Named a Finalist for the 2013 Red Herring Top 100 North America Award

April 3, 2013
New Data Highlighting CytomX's Probody Platform and EGFR Probody Drug Conjugate to be Presented at the AACR Annual Meeting 2013

2012

July 31, 2012
CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate

March 6, 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors

2011

October 6, 2011
CytomX Therapeutics Promotes Henry Lowman, Ph.D., to Chief Scientific Officer

August 11, 2011
CytomX Announces Appointment of Sean McCarthy as Chief Executive Officer

January 5, 2011
CytomX Therapeutics Appoints Sean McCarthy as Chief Business Officer

2010

November 12, 2010
CytomX Therapeutics Awarded Two Federal Research Grants under the Qualifying Therapeutic Discovery Project (QTDP) Program

September 23, 2010
CytomX Therapeutics Completes $30 Million Series B Financing